{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:59Z","timestamp":1776850499757,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>21-day-old rats were subjected to unilateral carotid ligation, then, after 2 h of\nrecovery, to 2 h of 8% hypoxia. Immediately following the insult they were treated with\neither flunarizine (30 mg\/kg, i.p.) or with an equal volume of diluent. We have previously\nshown similar doses of flunarizine to be neuroprotective when given preinsult. After 5 days\nthey were sacrificed for histological analysis. Cerebral injury was almost entirely confined to\nthe ligated side. Full-thickness cortical infarction was noted in 55% of controls (n = 29)\nversus 36% of flunarizine-treated rats (n = 28; p = 0.14). Mean damage scores for all areas\nassessed including cortex, striatum, and hippocampus were not significantly different. These\nobservations suggest that flunarizine is not significantly neuroprotective when given immediately\nafter severe hypoxia-ischemia.<\/jats:p>","DOI":"10.1159\/000457524","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:32Z","timestamp":1502471312000},"page":"205-209","source":"Crossref","is-referenced-by-count":6,"title":["Flunarizine, a Calcium Channel Antagonist, Is Not Neuroprotective when Given after Hypoxia-Ischemia in the Infant Rat"],"prefix":"10.1159","author":[{"given":"A.J.","family":"Gunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.D.","family":"Gluckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:46Z","timestamp":1776846886000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457524","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}